x

Posted 13 November, 2023

CohBar, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:CWBR in a 8-K filed on 13 November, 2023.


  Joseph J. Sarret, M.D., J.D., CohBar's President and Chief Executive Officer, at the direction of the Board, ceased to be an officer of CohBar, effective as of November 10, 2023.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of CohBar, Inc.
Health Care/Life Sciences • Biotechnology
CohBar, Inc. is a clinical stage biotechnology company, which engages in the research and development of mitochondria-based therapeutics targeting chronic and age-related diseases. The company was founded by Nir Barzilai, Pinchas Cohen, David Sinclair, John Amatruda, and Laura Cobb on October 19, 2007 and is headquartered in Menlo Park, CA.
Market Cap
$2.56M
View Company Details
CohBar, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Appointment of Director 


On November 6, 2023, the Board of Directors (the "Board") of CohBar, Inc. ("CohBar") resolved to increase the size of the Board from seven to eight directors and to appoint Craig R. Jalbert to the Board to fill the newly-created directorship and to hold office until the next annual meeting of stockholders and until the election and qualification of his successor and be subject to his earlier death, resignation or removal, in each case effective immediately. Mr. Jalbert has not been appointed to any committee of the Board and, as of the date hereof, is not expected to be appointed to any committee of the Board.


In connection with his appointment, Mr. Jalbert will be compensated in the amount of $10,000 per month until CohBar files a certificate of dissolution with the Secretary of State of the State of Delaware. If CohBar stockholders approve a dissolution of CohBar and the Board determines to implement the dissolution, following the filing of the certificate of dissolution with the Secretary of State of the State of Delaware, Mr. Jalbert will be compensated in the amount of $50,000 per year for a period of three years. There are no arrangements or understandings between Mr. Jalbert and any other person pursuant to which Mr. Jalbert was selected as a director. There is no information that is required to be disclosed with respect to Mr. Jalbert pursuant to Item 404(a) of Regulation S-K.


Departure of Directors and Officers 


On November 6, 2023, November 7, 2023 and November 9, 2023, each of Albion J. Fitzgerald, David L. Greenwood, Carol Nast, Misha Petkevich, Joseph J. Sarret, M.D., J.D., Effie Tozzo, Ph.D. and Joanne Yun, Ph.D., as applicable, notified the Board of his or her intention to resign from the Board and committees of the Board on which he or she served, effective November 10, 2023. None of the resignations were the result of any disagreements with CohBar or the Board on any matter relating to CohBar's operations, policies or practices. 


Joseph J. Sarret, M.D., J.D., CohBar's President and Chief Executive Officer, at the direction of the Board, ceased to be an officer of CohBar, effective as of November 10, 2023. Mr. Sarret's resignation was not the result of any disagreements with CohBar or the Board on any matter relating to CohBar's operations, policies or practices. 


Jeffery F. Biunno, CohBar's Chief Financial Officer, at the direction of the Board, ceased to be an officer of CohBar, effective as of November 10, 2023. Mr. Biunno's resignation was not the result of any disagreements with CohBar or the Board on any matter relating to CohBar's operations, policies or practices.